Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk

Area of Science:

• Cardiology
• Pharmacology
• Clinical Risk Assessment

Background:

• Patients with stable coronary artery disease (CAD) face elevated cardiovascular risks.
• Accurate individual risk stratification in these patients remains challenging.
• The EUROPA study population provided a basis for developing a new cardiovascular risk model.

Purpose of the Study:

• To develop a cardiovascular risk model for stable CAD patients.
• To assess if the benefits of long-term perindopril administration are modified by individual risk level.
• To identify key risk factors associated with cardiovascular events in stable CAD.

Main Methods:

• A total of 12,218 patients with stable CAD were enrolled.
• Patients received either 8 mg perindopril or a placebo.
• Baseline characteristics were analyzed for association with cardiovascular deaths or myocardial infarction (MI).

Main Results:

• Key risk factors identified included age >65, male gender, previous MI, stroke, diabetes, smoking, angina, high cholesterol, and high systolic blood pressure.
• Perindopril demonstrated consistent treatment benefits across high, intermediate, and low cardiovascular risk groups (HRs 0.88, 0.68, 0.83).
• The risk reduction achieved with perindopril was not significantly modified by the absolute risk level of the patients.

Conclusions:

• Established risk factors remain significant even after the development of coronary heart disease.
• Patients with moderate-to-high risk, particularly those with uncontrolled factors, show substantial gains from ACE-inhibition.
• Perindopril offers consistent cardiovascular risk reduction in stable CAD patients, irrespective of their baseline risk stratification.